{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:51:18Z","timestamp":1790920278815,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1016\/j.clim.2010.10.010","type":"journal-article","created":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T09:49:35Z","timestamp":1291196975000},"page":"162-171","source":"Crossref","is-referenced-by-count":26,"title":["Intravenous immunoglobulins exposed to heme (heme IVIG) are more efficient than IVIG in attenuating autoimmune diabetes"],"prefix":"10.1016","volume":"138","author":[{"given":"Sladjana","family":"Pavlovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nemanja","family":"Zdravkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan D.","family":"Dimitrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandar","family":"Djukic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nebojsa","family":"Arsenijevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tchavdar L.","family":"Vassilev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miodrag L.","family":"Lukic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2010.10.010_bb0005","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0165-5728(01)00243-0","article-title":"Polyspecific immunoglobulins (IVIg) suppress proliferation of human (auto) antigen-specific T cells with-out inducing apoptosis","volume":"114","author":"Aktas","year":"2001","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.clim.2010.10.010_bb0010","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immuneglobulin","volume":"345","author":"Kazatchkine","year":"2001","journal-title":"N Engl J. Med."},{"key":"10.1016\/j.clim.2010.10.010_bb0015","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMcibr0803649","article-title":"The antiinflammatory IgG","volume":"359","author":"Kaveri","year":"2008","journal-title":"N Engl J. Med."},{"key":"10.1016\/j.clim.2010.10.010_bb0020","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.autrev.2008.04.011","article-title":"Role of natural antibodies in immune homeostasis: IVIg perspective","volume":"7","author":"Vani","year":"2008","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.clim.2010.10.010_bb0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/135245859700300211","article-title":"Modulation of autoimmune responses by intravenous immunoglobulin (IVIg)","volume":"3","author":"Kaveri","year":"1997","journal-title":"Mult. Scler."},{"key":"10.1016\/j.clim.2010.10.010_bb0030","doi-asserted-by":"crossref","first-page":"19571","DOI":"10.1073\/pnas.0810163105","article-title":"Identification of a receptor required for the anti-inflammatory activity of IVIG","volume":"105","author":"Anthony","year":"2008","journal-title":"Proc. Natl Acad. Sci."},{"key":"10.1016\/j.clim.2010.10.010_bb0035","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/blood-2007-03-079947","article-title":"Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis","volume":"111","author":"Ephrem","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clim.2010.10.010_bb0040","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1097\/01.LAB.0000077982.70800.02","article-title":"Polyreactive autoantibodies purified from human intravenous immunoglobulins prevent the development of experimental autoimmune diseases","volume":"83","author":"Bruley-Rosset","year":"2003","journal-title":"Lab. Invest."},{"key":"10.1016\/j.clim.2010.10.010_bb0045","doi-asserted-by":"crossref","first-page":"764","DOI":"10.4049\/jimmunol.179.2.764","article-title":"Activating Fc gamma receptors participate in the development of autoimmune diabetes in NOD mice","volume":"179","author":"Inoue","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2010.10.010_bb0050","doi-asserted-by":"crossref","first-page":"6603","DOI":"10.4049\/jimmunol.177.10.6603","article-title":"Cyclophosphamide-induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4+CD25+Foxp3+ regulatory T cells","volume":"177","author":"Brode","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2010.10.010_bb0055","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.molimm.2008.12.023","article-title":"Regulatory T cells and ST2 signaling control diabetes induction with multiple low doses of streptozotocin","volume":"47","author":"Zdravkovic","year":"2009","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.clim.2010.10.010_bb0060","doi-asserted-by":"crossref","first-page":"26696","DOI":"10.1074\/jbc.M702751200","article-title":"Antibodies use hema as a cofactor to extend their pathogen elimination activity and to acquire new effector functions","volume":"282","author":"Dimitrov","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.clim.2010.10.010_bb0065","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-3083.2005.01568.x","article-title":"The autoreactivity of therapeutic intravenous immunoglobulin (IVIG) preparations depends on the fractionation methods used","volume":"61","author":"Djoumerska","year":"2005","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.clim.2010.10.010_bb0070","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1006\/jaut.1999.0331","article-title":"Acceleration of autoimmune diabetes by cyclophosphamide is associated with an enhanced IFN-gamma secretion pathway","volume":"13","author":"Ablamunits","year":"1999","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.clim.2010.10.010_bb0075","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1365-3083.2006.01893.x","article-title":"Iron ions and haeme modulate the binding properties of complement subcomponent C1q and of immunoglobulins","volume":"65","author":"Dimitrov","year":"2007","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.clim.2010.10.010_bb0080","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1006\/jaut.2000.0433","article-title":"Suppression of experimental autoimmune encephalomyelitis by intravenously administered polyclonal immunoglobulins","volume":"15","author":"Achiron","year":"2000","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.clim.2010.10.010_bb0085","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1172\/JCI117012","article-title":"Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. Upregulation of T cell proliferation and downregulation of tumor necrosis factor alpha secretion","volume":"93","author":"Achiron","year":"1994","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2010.10.010_bb0090","first-page":"240","article-title":"The therapeutic effect of intravenous immunoglobulins and vitamin C on the progression of experimental autoimmune myocarditis in the mouse","volume":"13","author":"Gong","year":"2007","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.clim.2010.10.010_bb0095","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s00415-008-3004-y","article-title":"IVIg in other autoimmune neurological disorders: current status and future prospects","volume":"255","author":"Dalakas","year":"2008","journal-title":"J. Neurol."},{"key":"10.1016\/j.clim.2010.10.010_bb0100","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1600-065X.1994.tb00855.x","article-title":"Pooled human IgG modulates cytokine production in lymphocytes and monocytes","volume":"139","author":"Andersson","year":"1994","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.clim.2010.10.010_bb0105","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1182\/blood.V100.5.1774.h81702001774_1774_1779","article-title":"Expression patterns of Th1 and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura (ITP) at presentation and their modulation by intravenous immunoglobulin G (IVIg) treatment: their role in prognosis","volume":"100","author":"Mouzaki","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clim.2010.10.010_bb0110","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2002-05-1447","article-title":"Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin","volume":"101","author":"Bayry","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clim.2010.10.010_bb0115","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/1389201033489775","article-title":"Intravenous immunoglobulin preparations and autoimmune disorders: mechanisms of action","volume":"4","author":"Ib\u00e1\u00f1ez","year":"2003","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.clim.2010.10.010_bb0120","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1126\/science.291.5503.484","article-title":"Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor","volume":"291","author":"Samuelsson","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.clim.2010.10.010_bb0125","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1074-7613(03)00080-3","article-title":"Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease","volume":"18","author":"Bruhns","year":"2003","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2010.10.010_bb0130","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/cbf.1470","article-title":"Type 1 diabetes: can exercise impair the autoimmune event? The l-arginine\/glutamine coupling hypothesis","volume":"26","author":"Krause","year":"2008","journal-title":"Cell Biochem. Funct."},{"key":"10.1016\/j.clim.2010.10.010_bb0135","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0092-8674(00)80856-9","article-title":"Regulatory T cells: key controllers of immunologic self-tolerance","volume":"101","author":"Sakaguchi","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.clim.2010.10.010_bb0140","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.4049\/jimmunol.179.8.5571","article-title":"Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function","volume":"179","author":"Kessel","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2010.10.010_bb0145","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2174\/1381612033392152","article-title":"Regulation of self-reactive T cells by human immunoglobulins \u2014 implications for multiple sclerosis therapy","volume":"9","author":"Aktas","year":"2003","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.clim.2010.10.010_bb0150","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri2138","article-title":"Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans","volume":"7","author":"Roncarolo","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.clim.2010.10.010_bb0155","doi-asserted-by":"crossref","first-page":"1p","DOI":"10.1038\/nri2138-c1","article-title":"Efficacy of regulatory T-cell immunotherapy: are inflammatory cytokines key determinants?","volume":"8","author":"Bayry","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.clim.2010.10.010_bb0160","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1196\/annals.1423.059","article-title":"Suppression of experimental autoimmune myasthenia gravis by intravenous immunoglobulin and isolation of a disease-specific IgG fraction","volume":"1110","author":"Fuchs","year":"2007","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.clim.2010.10.010_bb0165","first-page":"939","article-title":"Reversal by cyclophosphamide of tolerance in contact sensitization: tolerance induced by prior feeding with DNCB","volume":"28","author":"Polak","year":"1975","journal-title":"Immunology"},{"key":"10.1016\/j.clim.2010.10.010_bb0170","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/eji.1830180325","article-title":"Anti-suppressor effect of cyclophosphamide on the development of spontaneous diabetes in NOD mice","volume":"18","author":"Yasunami","year":"1988","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.clim.2010.10.010_bb0175","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/262077a0","article-title":"Enhancement of delayed hypersensitivity by depletion of suppressor T cells with cyclophosphamide in mice","volume":"262","author":"Mitsuoka","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.clim.2010.10.010_bb0180","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1084\/jem.145.2.455","article-title":"Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation ofantigen-specific cytotoxic T lymphocytes","volume":"145","author":"R\u00f6llinghoff","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2010.10.010_bb0185","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2337\/diabetes.38.4.441","article-title":"Cyclophosphamide-induced diabetes in NOD\/WEHI mice: evidence for suppression in spontaneous autoimmune diabetes mellitus","volume":"38","author":"Charlton","year":"1989","journal-title":"Diabetes"},{"key":"10.1016\/j.clim.2010.10.010_bb0190","first-page":"285","article-title":"Selective depletion of lymphoid tissue by cyclophosphamide","volume":"10","author":"Turk","year":"1972","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.clim.2010.10.010_bb0195","first-page":"493","article-title":"Functional aspects of the selective depletion of lymphoid tissue by cyclophosphamide","volume":"23","author":"Turk","year":"1972","journal-title":"Immunology"},{"key":"10.1016\/j.clim.2010.10.010_bb0200","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood-2005-02-0642","article-title":"Reduced frequencies and suppressive function of CD4+CD25 hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine","volume":"106","author":"Beyer","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clim.2010.10.010_bb0205","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/eji.200324181","article-title":"CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative","volume":"34","author":"Ghiringhelli","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.clim.2010.10.010_bb0210","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nm0302-240","article-title":"Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice","volume":"8","author":"Lee","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2010.10.010_bb0215","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1742-2094-7-51","article-title":"Hemin inhibits NO production by IL-1\u03b2-stimulated human astrocytes through induction of heme oxygenase-1 and reduction of p38 MAPK activation","volume":"7","author":"Sheng","year":"2010","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.clim.2010.10.010_bb0220","doi-asserted-by":"crossref","first-page":"567","DOI":"10.4161\/cc.6.5.3917","article-title":"Long-lasting expression of HO-1 delays progression of type I diabetes in NOD mice","volume":"6","author":"Li","year":"2007","journal-title":"Cell Cycle"}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661610007606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661610007606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,14]],"date-time":"2020-06-14T07:01:14Z","timestamp":1592118074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661610007606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S1521661610007606"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2010.10.010","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}